Takeda Pharmaceutical Company Limited ADR (TAK)
NYSE: TAKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TAK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $58.68B
- Forward P/E
- 34.66
- EPS (TTM)
- -$0.34
- Dividend yield
- 1088.73% ($200.00)
- Ex-dividend date
- Mar 31, 2025
- 52-week range
- 12.99 – 19.10
- Day range
- 18.14 – 18.46
- Volume / Avg
- 2.47M / 3.01M
- Beta
- —
- Shares outstanding
- 3.19B
- Next earnings
- Oct 29, 2026
52-week range
TAK stock today
Takeda Pharmaceutical (TAK) closed at $18.37 on Oct 7, up 1.49% (+$0.27), versus the S&P 500's 0.22% decline. At this level, TAK sits near the top of its 52-week range of $12.99 to $19.10: 3.8% below the high, set on Sep 17, 2026 and 41.4% above the low. TAK is up 17.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 27.0%.
Takeda Pharmaceutical has posted a net loss over the last twelve months (EPS of -$0.34), so its P/E ratio is not meaningful. Takeda Pharmaceutical's next earnings report is expected on Oct 29, 2026. Takeda Pharmaceutical pays an annual dividend of $200.00 per share, a 1088.73% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Takeda Pharmaceutical
Company profileTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Julie Kim
- Headquarters
- Chuo
- Employees
- 47,029
- IPO year
- 2018
- Website
- takeda.com
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$22.01+19.81%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $0.31
Dividends
Dividend history- Annual dividend
- $200.00
- Dividend yield
- 1088.73%
- Last payment
- $0.339
- Ex-dividend date
- Mar 31, 2025
TAK news
All TAK news- Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 TrialNasdaq
- Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis TrialNasdaq
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMDNasdaqKROS, REGN, TAK, PGEN
- Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock DownNasdaq
- Takeda Unveils $22.2 Mln CSR Collaborations Focused On Climate-Resilient Health; Stock UpNasdaq
- Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?NasdaqBMY, AMGN, TAK
- Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaTAK, MS
- Best Value Stocks to Buy for September 14thNasdaqSIG, TX, TAK
Takeda Pharmaceutical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TEVATeva Pharmaceutical Industries Limited | 39.18 | +0.13% | $45.70B | vs TAK |
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs TAK |
| REGNRegeneron Pharmaceuticals Inc. | 742.12 | +0.46% | $76.40B | vs TAK |
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs TAK |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs TAK |
| ZTSZoetis Inc. Class A | 71.55 | +0.31% | $29.57B | vs TAK |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs TAK |
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs TAK |
Indexes, lists and sector
Appears in lists
Takeda Pharmaceutical stock FAQ
What is Takeda Pharmaceutical's stock price today?
TAK last traded at $18.37 as of Oct 7, 4:00 PM EDT, up 1.49% on the day. Prices are delayed at least 15 minutes.
Does Takeda Pharmaceutical pay a dividend?
Yes. Takeda Pharmaceutical pays $200.00 per share annually, a 1088.73% yield. The most recent dividend of $0.339 had an ex-dividend date of Mar 31, 2025.
When is Takeda Pharmaceutical's next earnings date?
Takeda Pharmaceutical is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $0.31.
Who is Takeda Pharmaceutical's CEO?
Ms. Julie Kim is the chief executive officer of Takeda Pharmaceutical Company Limited ADR, which has about 47,029 employees.
What is the TAK 52-week high?
The 52-week high for TAK is $19.10 and the 52-week low is $12.99. The stock is currently 3.8% below its high.